Literature DB >> 22425494

Adjunctive surgery improves treatment outcomes among patients with multidrug-resistant and extensively drug-resistant tuberculosis.

Medea Gegia1, Iagor Kalandadze, Russel R Kempker, Matthew J Magee, Henry M Blumberg.   

Abstract

OBJECTIVES: To determine risk factors for poor outcomes among patients with pulmonary multidrug- or extensively drug-resistant (M/XDR) tuberculosis (TB) in Georgia.
METHODS: This was a prospective, population-based observational cohort study.
RESULTS: Among 380M/XDR-TB patients (mean age 38 years), 179 (47%) had a poor outcome: 59 (16%) died, 37 (10%) failed, and 83 (22%) defaulted. Newly diagnosed M/XDR-TB cases were significantly more likely to have a favorable outcome than retreatment cases (odds ratio (OR) 4.26, 95% confidence interval (CI) 1.99-9.10, p<0.001). In the multivariable analysis, independent risk factors for a poor treatment outcome included previous treatment history (OR 2.92, 95% CI 1.29-6.58), bilateral disease (OR 1.90, 95% CI 1.20-3.01), body mass index (BMI, kg/m(2)) ≤18.5 (OR 1.91, 95% CI 1.11-3.29), and XDR-TB (OR 2.28, 95% CI 1.11-4.71). Patients who underwent surgical resection (OR 0.27, 95% CI 0.11-0.64) and had sputum culture conversion by 4 months (OR 0.33, 95% CI 0.21-0.52) were significantly less likely to have poor treatment outcomes.
CONCLUSIONS: Adjunctive surgery appeared to be beneficial in treating patients with M/XDR-TB. Retreatment cases, XDR-TB, bilateral disease, and low BMI were associated with a poor outcome. Additional studies are needed to further define the apparent beneficial role of surgery in the treatment of M/XDR-TB.
Copyright © 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22425494      PMCID: PMC3786004          DOI: 10.1016/j.ijid.2011.12.018

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  19 in total

1.  Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis.

Authors:  Neel R Gandhi; Paul Nunn; Keertan Dheda; H Simon Schaaf; Matteo Zignol; Dick van Soolingen; Paul Jensen; Jaime Bayona
Journal:  Lancet       Date:  2010-05-22       Impact factor: 79.321

2.  Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study.

Authors:  C-Y Chiang; D A Enarson; M-C Yu; K-J Bai; R-M Huang; C-J Hsu; J Suo; T-P Lin
Journal:  Eur Respir J       Date:  2006-07-12       Impact factor: 16.671

3.  Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.

Authors:  Yong Soo Kwon; Yee Hyung Kim; Gee Young Suh; Man Pyo Chung; Hojoong Kim; O Jung Kwon; Yong Soo Choi; Kwhanmien Kim; Jhingook Kim; Young Mog Shim; Won-Jung Koh
Journal:  Clin Infect Dis       Date:  2008-08-15       Impact factor: 9.079

Review 4.  A consistent log-linear relationship between tuberculosis incidence and body mass index.

Authors:  Knut Lönnroth; Brian G Williams; Peter Cegielski; Christopher Dye
Journal:  Int J Epidemiol       Date:  2009-10-09       Impact factor: 7.196

5.  Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens.

Authors:  W W Yew; C K Chan; C H Chau; C M Tam; C C Leung; P C Wong; J Lee
Journal:  Chest       Date:  2000-03       Impact factor: 9.410

6.  Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome.

Authors:  Timothy H Holtz; Maya Sternberg; Steve Kammerer; Kayla F Laserson; Vija Riekstina; Evija Zarovska; Vija Skripconoka; Charles D Wells; Vaira Leimane
Journal:  Ann Intern Med       Date:  2006-05-02       Impact factor: 25.391

7.  Survival and predictors of outcomes in non-HIV-infected patients with extensively drug-resistant tuberculosis.

Authors:  D S Jeon; D H Kim; H S Kang; S H Hwang; J H Min; J H Kim; N M Sung; M W Carroll; S K Park
Journal:  Int J Tuberc Lung Dis       Date:  2009-05       Impact factor: 2.373

8.  Prevalence and risk factors for multidrug-resistant tuberculosis in the Republic of Georgia: a population-based study.

Authors:  N Lomtadze; R Aspindzelashvili; M Janjgava; V Mirtskhulava; A Wright; H M Blumberg; A Salakaia
Journal:  Int J Tuberc Lung Dis       Date:  2009-01       Impact factor: 2.373

9.  Treatment and follow-up of HIV-negative multidrug-resistant tuberculosis patients in an infectious diseases reference hospital, Buenos Aires, Argentina.

Authors:  D J Palmero; M Ambroggi; A Brea; M De Lucas; A Fulgenzi; D Martínez; C Mosca; R Musella; M Natiello; C Gonzalez; E Abbate
Journal:  Int J Tuberc Lung Dis       Date:  2004-06       Impact factor: 2.373

Review 10.  Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis.

Authors:  Evan W Orenstein; Sanjay Basu; N Sarita Shah; Jason R Andrews; Gerald H Friedland; Anthony P Moll; Neel R Gandhi; Alison P Galvani
Journal:  Lancet Infect Dis       Date:  2009-03       Impact factor: 25.071

View more
  15 in total

1.  The Impact of a Fogarty International Center-Supported Tuberculosis Research Training Program in the Country of Georgia.

Authors:  Russell R Kempker; Nestani Tukvadze; Lisa Sthreshley; Lisa Sharling; Dawn L Comeau; Matthew J Magee; Carlos Del Rio; Zaza Avaliani; Henry M Blumberg
Journal:  Am J Trop Med Hyg       Date:  2018-02-01       Impact factor: 2.345

2.  Clinical outcomes for multi- and extensively drug resistant tuberculosis patients with adjunctive resectional lung surgery in Beijing, China.

Authors:  Yan Ma; Yu Pang; Jian Du; Yuhong Liu; Liang Li; Weiwei Gao
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

Review 3.  The medical and surgical treatment of drug-resistant tuberculosis.

Authors:  Gregory L Calligaro; Loven Moodley; Greg Symons; Keertan Dheda
Journal:  J Thorac Dis       Date:  2014-03       Impact factor: 2.895

4.  Significant clinical impact of a rapid molecular diagnostic test (Genotype MTBDRplus assay) to detect multidrug-resistant tuberculosis.

Authors:  Maia Kipiani; Veriko Mirtskhulava; Nestani Tukvadze; Matthew Magee; Henry M Blumberg; Russell R Kempker
Journal:  Clin Infect Dis       Date:  2014-08-04       Impact factor: 9.079

5.  Favorable outcomes for multidrug and extensively drug resistant tuberculosis patients undergoing surgery.

Authors:  Sergo Vashakidze; Shota Gogishvili; Ketino Nikolaishvili; Nino Dzidzikashvili; Nestani Tukvadze; Henry M Blumberg; Russell R Kempker
Journal:  Ann Thorac Surg       Date:  2013-05-01       Impact factor: 4.330

6.  Outcomes of children treated for tuberculosis with second-line medications in Georgia, 2009-2011.

Authors:  M Gegia; H E Jenkins; I Kalandadze; J Furin
Journal:  Int J Tuberc Lung Dis       Date:  2013-05       Impact factor: 2.373

7.  Risk factors associated with loss to follow-up among multidrug-resistant tuberculosis patients in Georgia.

Authors:  G Kuchukhidze; A M V Kumar; P de Colombani; M Khogali; U Nanava; H M Blumberg; R R Kempker
Journal:  Public Health Action       Date:  2014-10-21

8.  Acquired Drug Resistance in Mycobacterium tuberculosis and Poor Outcomes among Patients with Multidrug-Resistant Tuberculosis.

Authors:  Russell R Kempker; Maia Kipiani; Veriko Mirtskhulava; Nestani Tukvadze; Matthew J Magee; Henry M Blumberg
Journal:  Emerg Infect Dis       Date:  2015-06       Impact factor: 6.883

9.  Adjunctive surgery versus medical treatment among patients with cavitary multidrug-resistant tuberculosis.

Authors:  Sergo A Vashakidze; Shota G Gogishvili; Ketino G Nikolaishvili; Zaza R Avaliani; Abivarma Chandrakumaran; Giorgi Sh Gogishvili; Mathew Magee; Henry M Blumberg; Russell R Kempker
Journal:  Eur J Cardiothorac Surg       Date:  2021-12-01       Impact factor: 4.534

Review 10.  The effect of surgery on the outcome of treatment for multidrug-resistant tuberculosis: a systematic review and meta-analysis.

Authors:  Rebecca C Harris; Mishal S Khan; Laura J Martin; Victoria Allen; David A J Moore; Katherine Fielding; Louis Grandjean
Journal:  BMC Infect Dis       Date:  2016-06-10       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.